Molecular characterization of the 17D-204 yellow fever vaccine

Vaccine

Volumn 33, Issue 41, 2015, Pages 5432-5436

  Salmona, Maud ^a   Gazaigne, Sandrine ^a   Mercier Delarue, Severine ^a   Garnier, Fabienne ^c   Korimbocus, Jehanara ^c   Colin de Verdière, Nathalie ^a   LeGoff, Jerome ^a   Roques, Pierre ^b   Simon, François ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CEA   (France)

^c Agence Nationale de la Sécurité du Médicament   (France)

Author keywords

Genetic diversity; Vaccine; Yellow fever

Indexed keywords

NUCLEOTIDE; VIRUS RNA; YELLOW FEVER VACCINE; LIVE VACCINE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL STUDY; GENE MUTATION; GENETIC DISTANCE; GENETIC VARIABILITY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRION; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; FRANCE; GENETIC VARIATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIXED INFECTION; YELLOW FEVER; YELLOW FEVER VIRUS;

CLONING, MOLECULAR; CLUSTER ANALYSIS; COINFECTION; FRANCE; GENETIC VARIATION; HIV INFECTIONS; HUMANS; SEQUENCE ANALYSIS, DNA; VACCINES, ATTENUATED; VIRAL PROTEINS; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84941876754     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.055     Document Type: Article

References (34)

1. Monath T.P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012, 11:427-448. 10.1586/erv.12.6.
2. Barrett A.D.T., Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007, 52:209-229. 10.1146/annurev.ento.52.110405.091454.
3. Stokes A., Bauer J.H., Hudson N.P. The transmission of yellow fever to macacus rhesus: preliminary note. J Am Med Assoc 1928, 90:253. 10.1001/jama.1928.02690310005002.
4. Stock N.K., Boschetti N., Herzog C., Appelhans M.S., Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012, 30:989-994. 10.1016/j.vaccine.2011.12.057.
5. Ferguson M., Shin J., Knezevic I., Minor P., Barrett A. WHO working group on technical specifications for manufacture and evaluation of yellow fever vaccines, Geneva, Switzerland, 13-14 May 2009. Vaccine 2010, 28:8236-8245. 10.1016/j.vaccine.2010.10.070.
6. Hahn C.S., Dalrymple J.M., Strauss J.H., Rice C.M. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci U S A 1987, 84:2019-2023.
7. Dupuy A., Despres P., Cahour A., Girard M., Bouloy M. Nucleotide sequence comparison of the genome of two 17D-204 yellow fever vaccines. Nucleic Acids Res 1989, 17:3989.
8. Heinz F.X., Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012, 30:4301-4306. 10.1016/j.vaccine.2011.09.114.
9. Centers for Disease Control and Prevention (CDC) Adverse events associated with 17D-derived yellow fever vaccination - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002, 51:989-993.
10. Staples J.E., Bocchini J.A., Rubin L., Fischer M., Centers for Disease Control and Prevention (CDC) Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015, 64(23):647-650.
11. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263. 10.1016/j.vaccine.2005.01.089.
12. Kengsakul K., Sathirapongsasuti K., Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thail Chotmaihet Thangphaet 2002, 85:131-134.
13. Breugelmans J.G., Lewis R.F., Agbenu E., Veit O., Jackson D., Domingo C., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31:1819-1829.
14. Domingo C., Niedrig M. Safety of 17D derived yellow fever vaccines. Expert Opin Drug Saf 2009, 8:211-221. 10.1517/14740330902808086.
15. Notes from the field: fatal yellow fever vaccine-associated viscerotropic disease - Oregon, September 2014 n.d. 2014, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6410a5.htm?s_cid=mm6410a5_w (accessed 26.04.15).
16. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011, 364:1326-1333. 10.1056/NEJMoa1009303.
17. Sambrook J., Russell D.W., Russell D.W. Molecular cloning: a laboratory manual (3-volume set) 2001, vol. 999. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
18. Kearse M., Moir R., Wilson A., Stones-Havas S., Cheung M., Sturrock S., et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinforma Oxf Engl 2012, 28:1647-1649. 10.1093/bioinformatics/bts199.
19. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980, 16:111-120.
20. Tamura K., Dudley J., Nei M., Kumar S. MEGA4 Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599. 10.1093/molbev/msm092.
21. Barban V., Girerd Y., Aguirre M., Gulia S., Pétiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007, 25:2941-2950. 10.1016/j.vaccine.2006.06.082.
22. WHO Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013 - recommendations. Vaccine 2015, 33:76-77. 10.1016/j.vaccine.2014.05.040.
23. Vratskikh O., Stiasny K., Zlatkovic J., Tsouchnikas G., Jarmer J., Karrer U., et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog 2013, 9:e1003458. 10.1371/journal.ppat.1003458.
24. Ryman K.D., Ledger T.N., Campbell G.A., Watowich S.J., Barrett A.D. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology 1998, 244:59-65. 10.1006/viro.1998.9057.
25. Ni H., Ryman K.D., Wang H., Saeed M.F., Hull R., Wood D., et al. Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol 2000, 74:2903-2906.
26. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439:344-348. 10.1038/nature04388.
27. Holland J.J., De La Torre J.C., Steinhauer D.A. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992, 176:1-20.
28. Beck A., Tesh R.B., Wood T.G., Widen S.G., Ryman K.D., Barrett A.D.T. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J Infect Dis 2014, 209:334-344. 10.1093/infdis/jit546.
29. Mutebi J-P., Wang H., Li L., Bryant J.E., Barrett A.D. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol 2001, 75:6999-7008.
30. Barrett A.D., Cross A.J., Crow T.J., Johnson J.A., Guest A.R., Dimmock N.J. Subclinical infections in mice resulting from the modulation of a lethal dose of Semliki Forest virus with defective interfering viruses: neurochemical abnormalities in the central nervous system. J Gen Virol 1986, 67(Pt 8):1727-1732.
31. Murgue B., Roche C., Chungue E., Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000, 60:432-438.
32. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9. 10.1086/315215.
33. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet Lond Engl 2001, 358:98-104.
34. Galler R., Pugachev K.V., Santos C.L., Ocran S.W., Jabor A.V., Rodrigues S.G., et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001, 290:309-319.